factor VII

(redirected from Coagulation factor VIIa)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Coagulation factor VIIa: BeneFix, Novoseven

factor VII

[′fak·tər ′se·vən]
(biochemistry)
A procoagulant, related to prothrombin, that is involved in the formation of a prothrombin-converting principle which transforms prothrombin to thrombin. Also known as stable factor.
References in periodicals archive ?
25, 2015 /PRNewswire/ --CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy.
These proteins include a recombinant form of human coagulation factor VIIa, which is being developed with partner LFB for the treatment of patients with hemophilia.
CSL Behring also continues to advance its long-acting recombinant fusion protein linking recombinant coagulation factor VIIa with recombinant albumin (rVIIa-FP) to control bleeding episodes in hemophilia patients who have inhibitors.
CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
GTC, together with its collaboration partner LFB Biotechnologies, has established the transgenic rabbit production system for its human coagulation factor VIIa (rhFVIIa) program and is well advanced in the preparations to initiate a Phase I study in the 2nd quarter of 2010.
The joint venture between GTC and LFB has prioritized the recombinant human coagulation factor VIIa program for development in clinical studies.

Full browser ?